Recxia Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 24-10-2024
- Paid Up Capital ₹ 0.20 M
as on 24-10-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -59.15%
(FY 2023)
- Profit -56.36%
(FY 2023)
- Ebitda -53.63%
(FY 2023)
- Net Worth 6.82%
(FY 2023)
- Total Assets -35.72%
(FY 2023)
About Recxia Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Satish Puri, Manish Pahwa, Kamal Sharma, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232PB2007PTC031183
- Company No.
031183
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Amritsar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Recxia Formulations Private Limited offer?
Recxia Formulations Private Limited offers a wide range of products and services, including Health Conditions, Liver Care.
Who are the key members and board of directors at Recxia Formulations?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Puri  | Director | 31-May-2007 | Current |
| Manish Pahwa | Additional Director | 01-Dec-2021 | Current |
| Kamal Sharma | Director | 31-May-2007 | Current |
| Pawan Kapoor | Additional Director | 01-Dec-2021 | Current |
Financial Performance of Recxia Formulations.
Recxia Formulations Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.15% decrease. The company also saw a substantial fall in profitability, with a 56.36% decrease in profit. The company's net worth moved up by a moderate rise of 6.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recxia Formulations?
In 2023, Recxia Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Recxia Formulations?
Recxia Formulations has a workforce of 4 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recxia Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recxia Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
